Open in web browser

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

Biosimilars

5 reasons to keep biosimilar names the same

The Healthcare Supply Chain Association (HSCA), the Generic Pharmaceutical Association (GPhA), and other healthcare stakeholders are calling on FDA to institute a clear policy for biologics and biosimilars. What you should know

FDA approves new heart failure drug

FDA approved Novartis’s sacubitril/valsartan (Entresto) tablets to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction (HFrEF). Details

CONTINUING EDUCATION

MTM essentials for COPD management: Part 1

This month's CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the Session Code: 15DT31-KTJ28.

To login to the Online CE Center, go to:
https://web2.uconn.edu/pharmacyce/login.php.
To review your registration page or to register, go to:
https://web2.uconn.edu/pharmacyce/program_register.php.
For a full list of courses, go to:
http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

US alleges Novartis paid kickbacks to specialty pharmacies

In a new lawsuit, the US government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants. Lawsuit details

July 15, 2015

Related Articles

Patent litigation could hold up biosimilars

FDA approves Corlanor to treat heart failure

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click here to contact Editorial. Sales, Reprints, Classified questions? Click here to contact the Sales Team.

ModernMedicine logo
UBM  logo

UBM MEDICA